Jazz Pharma Says FDA Again Defied Orphan Drug Exclusivity

By Hailey Konnath (June 22, 2023, 9:41 PM EDT) -- Jazz Pharma on Thursday asked a D.C. federal judge to block the U.S. Food and Drug Administration's "unlawful" approval of a rival narcolepsy treatment despite Jazz's exclusivity rights under the Orphan Drug Act, arguing that it showcases the FDA's "stark refusal" to implement the ODA as it should....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!